The Department of Veterans Affairs (VA) today announced a groundbreaking initiative to administer unapproved psychedelic substances to up to 2.1 million former service members, promising a “paradigm shift” in mental health care. The move, championed by the Trump administration, bypasses traditional regulatory approval processes, with officials citing an urgent need for "new perspectives" on post-traumatic stress and other service-related conditions.
"We've been doing talk therapy and antidepressants for decades, and frankly, some veterans are still just... sad," stated Dr. Maverick Vance, a newly appointed VA consultant and self-described "consciousness disruptor." Dr. Vance, whose previous experience includes running a multi-level marketing scheme for colloidal silver, added, "With psychedelics, we're not just treating symptoms; we're giving them a cosmic reboot. Think of it as a mental health hack, a fast-track to inner peace, or at least a really interesting Tuesday afternoon." He outlined plans for "Group Vision Quest Sessions" held in decommissioned mess halls, equipped with blacklights and a Spotify playlist curated by AI for "optimal spiritual unfolding."
The plan, internally dubbed "Project Tripwire," aims to streamline the existing, cumbersome veteran mental health infrastructure. By replacing lengthy individual therapy with single, potentially life-altering doses, the VA projects "unprecedented gains in efficiency" and "significant reductions in therapist payroll." Veterans will be encouraged to "bring a trusted friend or spirit guide" for integration support, as formal post-trip counseling services are still in development, pending budget reallocation from "boring old CBT programs." A pilot program involving a regional VA hospital successfully resulted in 30% fewer complaints about wait times, primarily because participants were reportedly too busy discussing the interconnectedness of all living things to fill out feedback forms.
Not everyone is convinced of the initiative's wisdom. Dr. Penelope Finch, head of the Institute for Responsible Pharmacological Innovation, voiced concerns. "Administering Schedule I substances on a mass scale without FDA oversight, proper clinical trials, or even a clear exit strategy seems...bold," Dr. Finch said, clutching her pearls so hard they almost dissolved. "We don't even have a standardized 'bad trip' protocol beyond 'wait it out,' which we feel is medically insufficient for 2.1 million people. And what about the long-term effects? Will they finally fix the VA backlog or just hallucinate that they fixed it?"
Despite the skepticism, VA Secretary Robert Wilkie reportedly signed off on the program after a brief meeting, commenting, "If it worked for Timothy Leary, it'll work for our heroes. Besides, we've already tried everything else, and this sounds like a lot less paperwork than building new clinics."
